A Phase 1 interventional study of Lenvatinib and Everolimus in Carcinoma, Renal Cell, sponsored by Eisai Co., Ltd.. Completed at 3 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-03-19.
Sponsored by Eisai Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing lenvatinib in Carcinoma, Renal Cell — 13 open to participants now, 17 under way, 2 of them phase 3. lenvatinib · Carcinoma, Renal Cell.
Among the 30 studies testing lenvatinib in Carcinoma, Renal Cell, this one is the 29th largest by enrollment, is the only one that started in 2015, is one of 4 in phase 1, and was the 2nd registered.
2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.
Browse Carcinoma, Renal Cell studies →13 of the 30 studies testing lenvatinib in Carcinoma, Renal Cell are open now, in 7 countries. Recruiting first, the newest first:
Jinling Hospital, China · Sites in China
Ages 18–80
Sun Yat-sen University · Sites in China
Ages 18–80
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+ · Healthy volunteers
Gustave Roussy, Cancer Campus, Grand Paris · Sites in Austria, Czechia, France and 1 more country
Ages 18+
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, lenvatinib is the treatment under test here. Read study by study →
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 23 · Phase 3 2 · Phase 4 1
First in 2010; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 43 across 1,566 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 30 across the 30 interventional studies. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 30 have an industry lead sponsor. The 10 most frequent:
Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.
Eisai Co., Ltd. has 6 studies filed under Carcinoma, Renal Cell — fewer than ten, so there is no comparison to draw.
4 of the studies testing lenvatinib in Carcinoma, Renal Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05319015University of Texas Southwestern Medical CenterNeoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus | 2026-12 |
| NCT07909265Cancer Institute and Hospital, Chinese Academy of Medical SciencesProspective Study of Cadonilimab With Lenvatinib in Renal Cell Carcinoma | 2027-07-01 |
| NCT05012371M.D. Anderson Cancer CenterLenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer | 2027-10-25 |
| NCT07256223Fudan UniversityA Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread | 2027-11-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 30 studies testing lenvatinib in Carcinoma, Renal Cell, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 1 study to investigate the tolerability and safety of lenvatinib in combination with Everolimus in participants with unresectable advanced or metastatic RCC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Lenvatinib · Drug: Everolimus
Also known as: Lenvatinib plus Everolimus orally once a day
Number of Participants Who Experienced Any Dose Limiting Toxicity (DLT)
DLT was defined as toxicity related to the combination therapy and was graded according to Common Terminology Criteria for Adverse Events version 4.03 (CTCAE v4.03).
Time frame: From first dose of study drug up to Cycle 1 Day 28 (Cycle length=28 days)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: Baseline up to 30 days after the last dose of study drug (up to approximately 21.5 months)
Cmax: Maximum Observed Plasma Concentration for Levatinib and Everolimus
Time frame: Cycle 1 Day 1 predose and at 1, 2, 4 ,8, and 24 hours postdose (Cycle length=28 days)
Css,Max: Maximum Observed Plasma Concentration at Steady State for Levatinib and Everolimus
Time frame: Cycle 1 Day 15 predose and at 1, 2, 4 ,8, and 24 hours postdose (Cycle length=28 days)
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Levatinib and Everolimus
Time frame: Cycle 1 Day 1 predose and at 1, 2, 4 ,8, and 24 hours postdose (Cycle length=28 days)
Tss,Max: Time to Reach the Maximum Plasma Concentration (Cmax) at Steady State for Levatinib and Everolimus
Time frame: Cycle 1 Day 15 predose and at 1, 2, 4 ,8, and 24 hours postdose (Cycle length=28 days)
AUC 0-t: Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration for Levatinib and Everolimus
Time frame: Cycle 1 Day 1 and Cycle 1 Day 15 predose and at 1, 2, 4 ,8, and 24 hours postdose (Cycle length=28 days)
Number of Participants With Best Overall Response (BOR)
BOR included complete response (CR), partial response (PR), stable disease (SD), and PD (progressive disease). BOR was assessed using Response Evaluation Criteria in Solid Tumor (RECIST) 1.1
Time frame: From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 23 months)
Objective Response Rate (ORR)
ORR was defined as the percentage of participants who achieved BOR of CR or PR. ORR was assessed using RECIST 1.1.
Time frame: From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 23 months)
Disease Control Rate (DCR)
DCR was defined as the percentage of participants who achieved BOR of CR, PR, or SD. DCR was assessed based on RECIST 1.1.
Time frame: From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 23 months)
Number of Participants With the Minimum Percent Change From Baseline in the Sum of Diameters of Target Lesions
Time frame: Baseline up to first tumor assessment at which diameter of target lesions were available (up to approximately 23 months)
Participants took part in the study at 3 sites in Japan from 01 July 2015 to 29 May 2017.
| Milestone | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|
| Started | 7 |
| Completed | 6 |
| Not completed | 1 |
| Withdrew: Incomplete dlt evaluation | 1 |
DLT was defined as toxicity related to the combination therapy and was graded according to Common Terminology Criteria for Adverse Events version 4.03 (CTCAE v4.03).
| participants | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|
| Number of Participants Who Experienced Any Dose Limiting Toxicity (DLT) | 0 |
| participants | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|
| TEAE | 7 |
| SAE | 3 |
| nanogram per milliliter (ng/mL) | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|
| Lenvatinib: Cycle 1 Day 1 | 289 ± 136 |
| Everolimus: Cycle 1 Day 1 | 39.1 ± 18.7 |
| ng/mL | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|
| Lenvatinib: Cycle 1 Day 15 | 257 ± 112 |
| Everolimus: Cycle 1 Day 15 | 41.5 ± 19.3 |
| hour | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|
| Lenvatinib: Cycle 1 Day 1 | 3.87 (0.95 to 3.87) |
| Everolimus: Cycle 1 Day 1 | 0.92 (0.82 to 1.10) |
| hour | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|
| Lenvatinib: Cycle 1 Day 15 | 3.77 (1.88 to 4.08) |
| Everolimus: Cycle 1 Day 15 | 0.97 (0.83 to 3.97) |
| hour * nanogram per milliliter (h*ng/mL) | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|
| Lenvatinib: Cycle 1 Day 1 | 2770 ± 1090 |
| Everolimus: Cycle 1 Day 1 | 211 ± 115 |
| Lenvatinib: Cycle 1 Day 15 | 3220 ± 1080 |
| Everolimus: Cycle 1 Day 15 | 401 ± 128 |
BOR included complete response (CR), partial response (PR), stable disease (SD), and PD (progressive disease). BOR was assessed using Response Evaluation Criteria in Solid Tumor (RECIST) 1.1
| participants | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|
| CR | 0 |
| PR | 5 |
| SD | 1 |
| PD | 1 |
ORR was defined as the percentage of participants who achieved BOR of CR or PR. ORR was assessed using RECIST 1.1.
| percentage of participants | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|
| Objective Response Rate (ORR) | 71.4 |
DCR was defined as the percentage of participants who achieved BOR of CR, PR, or SD. DCR was assessed based on RECIST 1.1.
| percentage of participants | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|
| Disease Control Rate (DCR) | 85.7 |
| participants | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|
| Less than or equal to (<=) -30% | 5 |
| Greater than (>) -30% to less than (<) 20% | 1 |
| Greater than or equal to (>=) 20% | 1 |
Collected over Baseline up to 30 days after the last dose of study drug (up to approximately 21.5 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lenvatinib 18 mg + Everolimus 5 mg | 0/7 (0%) | 3/7 (42.9%) | 7/7 (100%) |
| Event | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 1/7 |
| DehydrationMetabolism and nutrition disorders | 1/7 |
| Spinal column stenosisMusculoskeletal and connective tissue disorders | 1/7 |
| Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/7 |
| Event | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 7/7 |
| Decreased appetiteMetabolism and nutrition disorders | 6/7 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 6/7 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 6/7 |
| LeukopeniaBlood and lymphatic system disorders | 5/7 |
| LymphopeniaBlood and lymphatic system disorders | 5/7 |
| NeutropeniaBlood and lymphatic system disorders | 5/7 |
| FatigueGeneral disorders | 5/7 |
| Oedema peripheralGeneral disorders | 5/7 |
| Blood cholesterol increasedInvestigations | 5/7 |
The safety analysis set was the group of participants who received at least 1 dose of lenvatinib.
| Age, Continuous(years) | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|
| Mean | 65.7 ± 6.29 |
| Sex: Female, Male(Participants) | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|
| Female | 1 |
| Male | 6 |
| Ethnicity (NIH/OMB)(Participants) | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 7 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 7 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2015 to primary completion in May 2017, 22 months.
Results were first posted in Feb 2019, 1 year 8 months after primary completion.
Of 138 industry-sponsored phase 1 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's 22 months is below that.
Counting every sponsor, half of 220 studies reached it within 50 months; a quarter within 32 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lenvatinib · Everolimus